Biotech’s Strong Leasing Activity & Cap Rate Compression Favors Alexandria

are logo

Alexandria Real Estate Equities (NYSE:ARE) is an office REIT that has operated in the niche of science and technology campuses in urban innovation clusters since 1994. With an $11 billion total market capitalization, it has about 19 million ft.2 in rentable property and 12.3 million more near completion or in the planning stage. They are present in AAA locations, and 53 percent of annualized base rent from investment-grade tenants. The business is still enjoying tailwinds from the life and science industry, where technology and favorable regulations have fueled demand growth — something of which Alexandria is positioned to take advantage. A highlight of Q2 has been its Greater Boston assets.

The company sold 70 percent of 225 Binney at the heart of Kendall Square in Cambridge to TIAA-CREF. Management has been content with the number of interested high-quality buyers and the high value TIAA-CREF has paid, at 4.5 percent cash cap rate. They will continue monetizing select assets that will help promote pipeline development. They also succeeded in validating asset values in Cambridge, which have risen as a top innovation cluster.

Demand for their campus has been strong, with biotech companies willing to pay for premium real estate. During Q2, 1.9 million square feet — a record figure for the company — have been leased, 29 percent in the Greater Boston area.

Lease renewals and re-leasing of space increased 8.0 percent on a cash basis. FFO-per-share grew 10 percent to $1.31, and dividend went up 7 percent from $0.72 to $0.77. Same-property cash NOI increased 4.7 percent, and adjusted EBITDA margins for 2Q15 are 65 percent. Driven by strong leasing activity, guidance FFO-per-share increased $0.02 to $5.24.

Signup button

Source: Alexandria Real Estate Equities, Fast Graphs


Written by Heli Brecailo

Disclaimer: This newsletter is not engaged in rendering tax, accounting, or other professional advice through this publication. No statement in this issue is to be construed as a recommendation to buy or sell any security or other investment. Please do your own due diligence before making any investment decision. Some information presented in this publication has been obtained from third-party sources considered to be reliable. Sources are not required to make representations as to the accuracy of the information, however, and consequently the publisher cannot guarantee accuracy.

Disclosure: The author has no positions in any shares mentioned, and no plans to initiate any positions within the next 72 hours.​